It is most likely that in the near future we aim at specific treatment options for hyperphosphatemia, chronic microinflammation, and increased FGF-23 levels and may be also MC chymase inhibition in patients with CKD that might help to lower the exceedingly high cardiovascular risk in this particular population group. Here, FGF23 is linked to chronic kidney disease.